Sunday, February 07, 2016 10:12:09 PM
"Recent research has shown why [Ebolaside the first version] didn't work as well we're recreating the drug in this new format and we should have it ready for testing in the next 30 days."
http://video.foxbusiness.com/v/3789335851001/drug-to-treat-ebola-virus-coming-soon/?playlist_id=87185#sp=show-clips
~~Seymour, September 2014
"announced that it shipped several anti-Ebola nanoviricide drug candidates to an unnamed "hi-security bio-containment facility" for evaluation."
http://seekingalpha.com/news/2237136-nanoviricides-up-on-report-of-ebola-drug-progress
~~January 22, 2015
"Ebolacide2.0 failed. My inside sources have warned with specifics as to why."
~~Rawnoc, January 2015 with a stock price over $3.00
Yes, you repeated what was already known from Ebolacide 1.0. Congrats! My inside sources warned about Ebolacide 2.0's failure -- and why -- after it was created and submitted for testing and failed.
As I've been saying since $6 per share, continue to ignore me at your own financial peril.
The SwingTrade Portfolio was up 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454
Recent NNVC News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
